{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:09:25Z","timestamp":1790766565027,"version":"4.1.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1249-5","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T21:14:54Z","timestamp":1488921294000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Mechanistic rationales for targeting interleukin-17A in spondyloarthritis"],"prefix":"10.1186","volume":"19","author":[{"given":"Siba P.","family":"Raychaudhuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti K.","family":"Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,8]]},"reference":[{"key":"1249_CR1","unstructured":"2014 ACR\/SAA\/SPARTAN recommendations for the management of axial spondyloarthritis, including ankylosing spondylitis, and children with the enthesitis-related arthritis form of juvenile idiopathic arthritis. Project plan. http:\/\/www.rheumatology.org\/Portals\/0\/Files\/Axial%20SpA%20Project%20Plan.pdf . Accessed 30 Aug 2016."},{"key":"1249_CR2","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s10067-015-2961-7","volume":"34","author":"SK Raychaudhuri","year":"2015","unstructured":"Raychaudhuri SK, Saxena A, Raychaudhuri SP. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol. 2015;34:1019\u201323.","journal-title":"Clin Rheumatol"},{"key":"1249_CR3","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10067-010-1646-5","volume":"30","author":"AK Singh","year":"2011","unstructured":"Singh AK, Misra R, Aggarwal A. Th-17 associated cytokines in patients with reactive arthritis\/undifferentiated spondyloarthropathy. Clin Rheumatol. 2011;30:771\u20136.","journal-title":"Clin Rheumatol"},{"key":"1249_CR4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1586\/1744666X.2015.1039514","volume":"11","author":"D Wendling","year":"2015","unstructured":"Wendling D. Treating to target in axial spondyloarthritis: defining the target and the arrow. Expert Rev Clin Immunol. 2015;11:691\u20133.","journal-title":"Expert Rev Clin Immunol"},{"key":"1249_CR5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.rdc.2012.09.003","volume":"38","author":"C Stolwijk","year":"2012","unstructured":"Stolwijk C, Boonen A, van Tubergen A, Reveille JD. Epidemiology of spondyloarthritis. Rheum Dis Clin North Am. 2012;38:441\u201376.","journal-title":"Rheum Dis Clin North Am"},{"key":"1249_CR6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/acr.21621","volume":"64","author":"JD Reveille","year":"2012","unstructured":"Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res (Hoboken). 2012;64:905\u201310.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1249_CR7","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar3781","volume":"14","author":"A Mitra","year":"2012","unstructured":"Mitra A, Raychaudhuri SK, Raychaudhuri SP. Functional role of IL-22 in psoriatic arthritis. Arthritis Res Ther. 2012;14:R65.","journal-title":"Arthritis Res Ther"},{"key":"1249_CR8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","volume":"11","author":"E Lubberts","year":"2015","unstructured":"Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11:415\u201329.","journal-title":"Nat Rev Rheumatol"},{"key":"1249_CR9","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4\u2212CD8\u2212 entheseal resident T cells. Nat Med. 2012;18:1069\u201376.","journal-title":"Nat Med"},{"key":"1249_CR10","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","volume":"35","author":"Y Cai","year":"2011","unstructured":"Cai Y, Shen X, Ding C, Qi C, Li K, Li X, et al. Pivotal role of dermal IL-17-producing \u03b3\u03b4 T cells in skin inflammation. Immunity. 2011;35:596\u2013610.","journal-title":"Immunity"},{"key":"1249_CR11","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2002-05-1461","volume":"101","author":"M Numasaki","year":"2003","unstructured":"Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood. 2003;101:2620\u20137.","journal-title":"Blood"},{"key":"1249_CR12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12016-012-8307-1","volume":"44","author":"SP Raychaudhuri","year":"2013","unstructured":"Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44:183\u201393.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1249_CR13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/jid.2014.426","volume":"135","author":"M Yamamoto","year":"2015","unstructured":"Yamamoto M, Nakajima K, Takaishi M, Kitaba S, Magata Y, Kataoka S, et al. Psoriatic inflammation facilitates the onset of arthritis in a mouse model. J Invest Dermatol. 2015;135:445\u201353.","journal-title":"J Invest Dermatol"},{"key":"1249_CR14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00296-015-3387-x","volume":"36","author":"M Rossini","year":"2016","unstructured":"Rossini M, Viapiana O, Adami S, Idolazzi L, Fracassi E, Gatti D. Focal bone involvement in inflammatory arthritis: the role of IL17. Rheumatol Int. 2016;36:469\u201382.","journal-title":"Rheumatol Int"},{"key":"1249_CR15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/art.38291","volume":"66","author":"JA Smith","year":"2014","unstructured":"Smith JA, Colbert RA. The interleukin-23\/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol. 2014;66:231\u201341.","journal-title":"Arthritis Rheumatol"},{"key":"1249_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbspin.2014.08.003","volume":"82","author":"D Wendling","year":"2015","unstructured":"Wendling D, Guillot X, Prati C. The IL-23\/Th 17 pathway in spondyloarthritis: the royal road? Joint Bone Spine. 2015;82:1\u20134.","journal-title":"Joint Bone Spine"},{"key":"1249_CR17","doi-asserted-by":"crossref","first-page":"780","DOI":"10.4049\/jimmunol.1500909","volume":"195","author":"HR Conti","year":"2015","unstructured":"Conti HR, Gaffen SL. IL-17-mediated immunity to the opportunistic fungal pathogen candida albicans. J Immunol. 2015;195:780\u20138.","journal-title":"J Immunol"},{"key":"1249_CR18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","volume":"9","author":"SL Gaffen","year":"2009","unstructured":"Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556\u201367.","journal-title":"Nat Rev Immunol"},{"key":"1249_CR19","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.4049\/jimmunol.167.2.1004","volume":"167","author":"E Lubberts","year":"2001","unstructured":"Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol. 2001;167:1004\u201313.","journal-title":"J Immunol"},{"key":"1249_CR20","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.4049\/jimmunol.170.5.2655","volume":"170","author":"E Lubberts","year":"2003","unstructured":"Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-\u03baB ligand\/osteoprotegerin balance. J Immunol. 2003;170:2655\u201362.","journal-title":"J Immunol"},{"key":"1249_CR21","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/art.38638","volume":"66","author":"H Benham","year":"2014","unstructured":"Benham H, Rehaume LM, Hasnain SZ, Velasco J, Baillet AC, Ruutu M, et al. Interleukin-23 mediates the intestinal response to microbial \u03b2-1,3-glucan and the development of spondyloarthritis pathology in SKG mice. Arthritis Rheumatol. 2014;66:1755\u201367.","journal-title":"Arthritis Rheumatol"},{"key":"1249_CR22","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"RH Duerr","year":"2006","unstructured":"Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314:1461\u20133.","journal-title":"Science"},{"key":"1249_CR23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","volume":"80","author":"M Cargill","year":"2007","unstructured":"Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80:273\u201390.","journal-title":"Am J Hum Genet"},{"key":"1249_CR24","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/ng.2007.17","volume":"39","author":"PR Burton","year":"2007","unstructured":"Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, Clayton DG, Cardon LR, Craddock N, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39:1329\u201337.","journal-title":"Nat Genet"},{"key":"1249_CR25","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.39732","volume":"68","author":"A Reinhardt","year":"2016","unstructured":"Reinhardt A, Yevsa T, Worbs T, Lienenklaus S, Sandrock I, Oberd\u00f6rfer L, et al. Interleukin-23-dependent \u03b3\/\u03b4 T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice. Arthritis Rheumatol. 2016;68:2476\u201386.","journal-title":"Arthritis Rheumatol"},{"key":"1249_CR26","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/art.20001","volume":"50","author":"E Lubberts","year":"2004","unstructured":"Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 2004;50:650\u20139.","journal-title":"Arthritis Rheum"},{"key":"1249_CR27","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1136\/annrheumdis-2013-204782","volume":"74","author":"IE Adamopoulos","year":"2015","unstructured":"Adamopoulos IE, Suzuki E, Chao CC, Gorman D, Adda S, Maverakis E, et al. IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis. Ann Rheum Dis. 2015;74:1284\u201392.","journal-title":"Ann Rheum Dis"},{"key":"1249_CR28","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","volume":"58","author":"C Jandus","year":"2008","unstructured":"Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum. 2008;58:2307\u201317.","journal-title":"Arthritis Rheum"},{"key":"1249_CR29","first-page":"2285","volume":"34","author":"R Singh","year":"2007","unstructured":"Singh R, Aggarwal A, Misra R. Th1\/Th17 cytokine profiles in patients with reactive arthritis\/undifferentiated spondyloarthropathy. J Rheumatol. 2007;34:2285\u201390.","journal-title":"J Rheumatol"},{"key":"1249_CR30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10875-012-9774-0","volume":"33","author":"L Xueyi","year":"2013","unstructured":"Xueyi L, Lina C, Zhenbiao W, Qing H, Qiang L, Zhu P. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-\u03b1 therapy. J Clin Immunol. 2013;33:151\u201361.","journal-title":"J Clin Immunol"},{"key":"1249_CR31","first-page":"529","volume":"52","author":"J Londono","year":"2012","unstructured":"Londono J, Romero-Sanchez MC, Torres VG, Bautista WA, Fernandez DJ, de Avila QA, et al. The association between serum levels of potential biomarkers with the presence of factors related to the clinical activity and poor prognosis in spondyloarthritis. Rev Bras Reumatol. 2012;52:529\u201344.","journal-title":"Rev Bras Reumatol"},{"key":"1249_CR32","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/art.39649","volume":"68","author":"F Ciccia","year":"2016","unstructured":"Ciccia F, Guggino G, Ferrante A, Raimondo S, Bignone R, Rodolico V, et al. Interleukin-9 overexpression and Th9 polarization characterize the inflamed gut, the synovial tissue, and the peripheral blood of patients with psoriatic arthritis. Arthritis Rheumatol. 2016;68:1922\u201331.","journal-title":"Arthritis Rheumatol"},{"key":"1249_CR33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","volume":"359","author":"SP Raychaudhuri","year":"2012","unstructured":"Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem. 2012;359:419\u201329.","journal-title":"Mol Cell Biochem"},{"key":"1249_CR34","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/rheumatology\/keu382","volume":"54","author":"DT Jansen","year":"2015","unstructured":"Jansen DT, Hameetman M, van Bergen J, Huizinga TW, van der Heijde D, Toes RE, et al. IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities. Rheumatology (Oxford). 2015;54:728\u201335.","journal-title":"Rheumatology (Oxford)"},{"key":"1249_CR35","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/art.33507","volume":"64","author":"TJ Kenna","year":"2012","unstructured":"Kenna TJ, Davidson SI, Duan R, Bradbury LA, McFarlane J, Smith M, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 2012;64:1420\u20139.","journal-title":"Arthritis Rheum"},{"key":"1249_CR36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/art.33396","volume":"64","author":"T Noordenbos","year":"2012","unstructured":"Noordenbos T, Yeremenko N, Gofita I, van de Sande M, Tak PP, Ca\u0148ete JD, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2012;64:99\u2013109.","journal-title":"Arthritis Rheum"},{"key":"1249_CR37","first-page":"S10","volume":"27","author":"RJ Lories","year":"2009","unstructured":"Lories RJ, Baeten DL. Differences in pathophysiology between rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol. 2009;27:S10\u20134.","journal-title":"Clin Exp Rheumatol"},{"key":"1249_CR38","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","volume":"66","author":"B Menon","year":"2014","unstructured":"Menon B, Gullick NJ, Walter GJ, Rajasekhar M, Garrood T, Evans HG, et al. Interleukin-17\u2009+\u2009CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol. 2014;66:1272\u201381.","journal-title":"Arthritis Rheumatol"},{"key":"1249_CR39","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.berh.2014.10.019","volume":"28","author":"F Bosch Van den","year":"2014","unstructured":"Van den Bosch F, Deodhar A. Treatment of spondyloarthritis beyond TNF-alpha blockade. Best Pract Res Clin Rheumatol. 2014;28:819\u201327.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1249_CR40","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/S0140-6736(13)61913-3","volume":"382","author":"RA Colbert","year":"2013","unstructured":"Colbert RA, Ward MM. 17 and 23: prime numbers for ankylosing spondylitis? Lancet. 2013;382:1682\u20133.","journal-title":"Lancet"},{"key":"1249_CR41","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2217\/imt.15.28","volume":"7","author":"E Toussirot","year":"2015","unstructured":"Toussirot E. Biologics in spondyloarthritis: TNF\u03b1 inhibitors and other agents. Immunotherapy. 2015;7:669\u201381.","journal-title":"Immunotherapy"},{"key":"1249_CR42","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1517\/14712598.2014.967211","volume":"14","author":"RJ Lories","year":"2014","unstructured":"Lories RJ, de Vlam K. Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity. Expert Opin Biol Ther. 2014;14:1825\u201336.","journal-title":"Expert Opin Biol Ther"},{"key":"1249_CR43","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3899\/jrheum.141001","volume":"42","author":"S Rohekar","year":"2015","unstructured":"Rohekar S, Chan J, Tse SM, Haroon N, Chandran V, Bessette L, et al. 2014 Update of the Canadian Rheumatology Association\/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis. Part II: specific management recommendations. J Rheumatol. 2015;42:665\u201381.","journal-title":"J Rheumatol"},{"key":"1249_CR44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis\u2014results of two phase 3 trials. N Engl J Med. 2014;371:326\u201338.","journal-title":"N Engl J Med"},{"key":"1249_CR45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541\u201351.","journal-title":"Lancet"},{"key":"1249_CR46","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137\u201346.","journal-title":"Lancet"},{"key":"1249_CR47","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534\u201348.","journal-title":"N Engl J Med"},{"key":"1249_CR48","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329\u201339.","journal-title":"N Engl J Med"},{"key":"1249_CR49","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"D Thaci","year":"2015","unstructured":"Thaci D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"1249_CR50","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273\u201386.","journal-title":"Br J Dermatol"},{"key":"1249_CR51","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318\u201328.","journal-title":"N Engl J Med"},{"key":"1249_CR52","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaad.2015.08.057","volume":"74","author":"MJ Danesh","year":"2016","unstructured":"Danesh MJ, Kimball AB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol. 2016;74:190\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"1249_CR53","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2016","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2016;76:79\u201387.","journal-title":"Ann Rheum Dis"},{"key":"1249_CR54","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705\u201313.","journal-title":"Lancet"},{"key":"1249_CR55","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/annrheumdis-2015-207544","volume":"75","author":"X Baraliakos","year":"2016","unstructured":"Baraliakos X, Borah B, Braun J, Baeten D, Laurent D, Sieper J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. 2016;75:408\u201312.","journal-title":"Ann Rheum Dis"},{"key":"1249_CR56","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","volume":"72","author":"MC Genovese","year":"2013","unstructured":"Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013;72:863\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1249_CR57","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.38617","volume":"66","author":"MC Genovese","year":"2014","unstructured":"Genovese MC, Greenwald M, Cho CS, Berman A, Jin L, Cameron GS, et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2014;66:1693\u2013704.","journal-title":"Arthritis Rheumatol"},{"key":"1249_CR58","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3899\/jrheum.150117","volume":"43","author":"W Tlustochowicz","year":"2016","unstructured":"Tlustochowicz W, Rahman P, Seriolo B, Krammer G, Porter B, Widmer A, et al. Efficacy and safety of subcutaneous and intravenous loading dose regimens of secukinumab in patients with active rheumatoid arthritis: results from a randomized phase II study. J Rheumatol. 2016;43:495\u2013503.","journal-title":"J Rheumatol"},{"key":"1249_CR59","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3899\/jrheum.140831","volume":"43","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Braun DK, Erickson JS, Berclaz PY, Banerjee S, Heffernan MP, et al. Safety and efficacy of open-label subcutaneous ixekizumab treatment for 48 weeks in a phase II study in biologic-naive and TNF-IR patients with rheumatoid arthritis. J Rheumatol. 2016;43:289\u201397.","journal-title":"J Rheumatol"},{"key":"1249_CR60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/kev258","volume":"55","author":"GR Burmester","year":"2016","unstructured":"Burmester GR, Durez P, Shestakova G, Genovese MC, Schulze-Koops H, Li Y, et al. Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. Rheumatology (Oxford). 2016;55:49\u201355.","journal-title":"Rheumatology (Oxford)"},{"key":"1249_CR61","first-page":"3156","volume":"8","author":"HZ Xiong","year":"2015","unstructured":"Xiong HZ, Gu JY, He ZG, Chen WJ, Zhang X, Wang JY, et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8:3156\u201372.","journal-title":"Int J Clin Exp Med"},{"key":"1249_CR62","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","volume":"122","author":"E Letko","year":"2015","unstructured":"Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122:939\u201348.","journal-title":"Ophthalmology"},{"key":"1249_CR63","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cyto.2013.03.013","volume":"62","author":"JB Golden","year":"2013","unstructured":"Golden JB, McCormick TS, Ward NL. IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine. 2013;62:195\u2013201.","journal-title":"Cytokine"},{"key":"1249_CR64","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijcard.2011.08.849","volume":"163","author":"SP Barry","year":"2013","unstructured":"Barry SP, Ounzain S, McCormick J, Scarabelli TM, Chen-Scarabelli C, Saravolatz LI, et al. Enhanced IL-17 signalling following myocardial ischaemia\/reperfusion injury. Int J Cardiol. 2013;163:326\u201334.","journal-title":"Int J Cardiol"},{"key":"1249_CR65","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1152\/advan.00063.2013","volume":"38","author":"DW Trott","year":"2014","unstructured":"Trott DW, Harrison DG. The immune system in hypertension. Adv Physiol Educ. 2014;38:20\u20134.","journal-title":"Adv Physiol Educ"},{"key":"1249_CR66","first-page":"130","volume":"125","author":"DG Harrison","year":"2014","unstructured":"Harrison DG. The immune system in hypertension. Trans Am Clin Climatol Assoc. 2014;125:130\u20138. discussion 138\u201340.","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"1249_CR67","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/jch.12612","volume":"17","author":"W Yao","year":"2015","unstructured":"Yao W, Sun Y, Wang X, Niu K. Elevated serum level of interleukin 17 in a population with prehypertension. J Clin Hypertens (Greenwich). 2015;17:770\u20134.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1249_CR68","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.14-1678","volume":"147","author":"A Hautefort","year":"2015","unstructured":"Hautefort A, Girerd B, Montani D, Cohen-Kaminsky S, Price L, Lambrecht BN, et al. T-helper 17 cell polarization in pulmonary arterial hypertension. Chest. 2015;147:1610\u201320.","journal-title":"Chest"},{"key":"1249_CR69","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cca.2010.10.027","volume":"412","author":"X Zhang","year":"2011","unstructured":"Zhang X, Pei F, Zhang M, Yan C, Huang M, Wang T, et al. Interleukin-17A gene variants and risk of coronary artery disease: a large angiography-based study. Clin Chim Acta. 2011;412:327\u201331.","journal-title":"Clin Chim Acta"},{"key":"1249_CR70","doi-asserted-by":"crossref","first-page":"e0114943","DOI":"10.1371\/journal.pone.0114943","volume":"10","author":"G Vargas-Alarc\u00f3n","year":"2015","unstructured":"Vargas-Alarc\u00f3n G, Angeles-Mart\u00ednez J, Villarreal-Molina T, Alvarez-Le\u00f3n E, Posadas-S\u00e1nchez R, Cardoso-Salda\u00f1a G, et al. Interleukin-17A gene haplotypes are associated with risk of premature coronary artery disease in Mexican patients from the Genetics of Atherosclerotic Disease (GEA) study. PLoS One. 2015;10:e0114943.","journal-title":"PLoS One"},{"key":"1249_CR71","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3899\/jrheum.111244","volume":"39","author":"SP Raychaudhuri","year":"2012","unstructured":"Raychaudhuri SP. Comorbidities of psoriatic arthritis\u2014metabolic syndrome and prevention: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39:437\u201340.","journal-title":"J Rheumatol"},{"key":"1249_CR72","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693\u2013700.","journal-title":"Gut"},{"key":"1249_CR73","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.3748\/wjg.v20.i12.3255","volume":"20","author":"XR Xu","year":"2014","unstructured":"Xu XR, Liu CQ, Feng BS, Liu ZJ. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2014;20:3255\u201364.","journal-title":"World J Gastroenterol"},{"key":"1249_CR74","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","volume":"75","author":"PC Kerkhof van de","year":"2016","unstructured":"van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75:83\u201398. e4.","journal-title":"J Am Acad Dermatol"},{"key":"1249_CR75","doi-asserted-by":"publisher","unstructured":"Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2016. doi: 10.1016\/j.jaad.2016.10.027 .","DOI":"10.1016\/j.jaad.2016.10.027"},{"key":"1249_CR76","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00018-012-1163-6","volume":"70","author":"JS Kim","year":"2013","unstructured":"Kim JS, Jordan MS. Diversity of IL-17-producing T lymphocytes. Cell Mol Life Sci. 2013;70:2271\u201390.","journal-title":"Cell Mol Life Sci"},{"key":"1249_CR77","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nri3365","volume":"13","author":"H Spits","year":"2013","unstructured":"Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate lymphoid cells\u2014a proposal for uniform nomenclature. Nat Rev Immunol. 2013;13:145\u20139.","journal-title":"Nat Rev Immunol"},{"key":"1249_CR78","doi-asserted-by":"crossref","first-page":"6145810","DOI":"10.1155\/2016\/6145810","volume":"2016","author":"R Kugyelka","year":"2016","unstructured":"Kugyelka R, Kohl Z, Olasz K, Mikecz K, Rauch TA, Glant TT, et al. Enigma of IL-17 and Th17 cells in rheumatoid arthritis and in autoimmune animal models of arthritis. Mediators Inflamm. 2016;2016:6145810.","journal-title":"Mediators Inflamm"},{"key":"1249_CR79","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","volume":"43","author":"JS Lee","year":"2015","unstructured":"Lee JS, Tato CM, Joyce-Shaikh B, Gulen MF, Cayatte C, Chen Y, et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. Immunity. 2015;43:727\u201338.","journal-title":"Immunity"},{"key":"1249_CR80","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.immuni.2009.06.020","volume":"31","author":"B Martin","year":"2009","unstructured":"Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity. 2009;31:321\u201330.","journal-title":"Immunity"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1249-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T08:09:00Z","timestamp":1498378140000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1249-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,8]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1249"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1249-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,8]]},"article-number":"51"}}